CA2867456A1 - Combination therapies including inhibitors of the extracellular domain of e-cadherin - Google Patents

Combination therapies including inhibitors of the extracellular domain of e-cadherin Download PDF

Info

Publication number
CA2867456A1
CA2867456A1 CA2867456A CA2867456A CA2867456A1 CA 2867456 A1 CA2867456 A1 CA 2867456A1 CA 2867456 A CA2867456 A CA 2867456A CA 2867456 A CA2867456 A CA 2867456A CA 2867456 A1 CA2867456 A1 CA 2867456A1
Authority
CA
Canada
Prior art keywords
secad
agent
cadherin
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2867456A
Other languages
English (en)
French (fr)
Inventor
Sabine Brouxhon
Stephanos Kyrkanides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of CA2867456A1 publication Critical patent/CA2867456A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CA2867456A 2012-03-15 2013-03-15 Combination therapies including inhibitors of the extracellular domain of e-cadherin Abandoned CA2867456A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611390P 2012-03-15 2012-03-15
US61/611,390 2012-03-15
US201261736475P 2012-12-12 2012-12-12
US61/736,475 2012-12-12
PCT/US2013/032656 WO2013138790A1 (en) 2012-03-15 2013-03-15 Combination therapies including inhibitors of the extracellular domain of e-cadherin

Publications (1)

Publication Number Publication Date
CA2867456A1 true CA2867456A1 (en) 2013-09-19

Family

ID=49161879

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2867456A Abandoned CA2867456A1 (en) 2012-03-15 2013-03-15 Combination therapies including inhibitors of the extracellular domain of e-cadherin

Country Status (8)

Country Link
US (2) US20150037354A1 (enExample)
EP (1) EP2844270A4 (enExample)
JP (1) JP2015514062A (enExample)
KR (1) KR20140138956A (enExample)
CN (1) CN104519899A (enExample)
CA (1) CA2867456A1 (enExample)
RU (1) RU2014141114A (enExample)
WO (1) WO2013138790A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2895623B1 (en) 2012-09-17 2018-08-22 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for selection of treatment responsive patients
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
EA201691896A1 (ru) 2014-03-21 2017-01-30 Аджиос Фармасьютикалз, Инк. Соединения и способы их применения
RS58957B1 (sr) * 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
CN111208283B (zh) * 2018-11-21 2023-09-26 中国科学院分子细胞科学卓越创新中心 增效的肿瘤抑制组合物及其应用
CN115040695B (zh) * 2021-03-09 2023-10-13 南开大学 一种基于VE-cad-Fc/N-cad-Fc的融合蛋白活性界面的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT414097B (de) * 2004-06-25 2006-09-15 Petzelbauer Peter Dr Pharmazeutische zubereitung zur behandlung von schock
AU2010242338B2 (en) * 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
WO2012058418A2 (en) * 2010-10-27 2012-05-03 The Research Foundation Of State University Of New York Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy

Also Published As

Publication number Publication date
EP2844270A1 (en) 2015-03-11
JP2015514062A (ja) 2015-05-18
KR20140138956A (ko) 2014-12-04
RU2014141114A (ru) 2016-05-10
EP2844270A4 (en) 2016-01-27
US20190008957A1 (en) 2019-01-10
WO2013138790A1 (en) 2013-09-19
US20150037354A1 (en) 2015-02-05
CN104519899A (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
US20210380671A1 (en) Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
US20190008957A1 (en) Combination therapies including inhibitors of the extracellular domain of e-cadherin
CN110546277B (zh) 用于癌症的诊断和治疗方法
JP2021001176A (ja) Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法
HK1204950A1 (en) Binding agents that modulate the hippo pathway and uses thereof
JP2018529719A (ja) Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
CN113196061A (zh) 肉瘤样肾癌的诊断和治疗方法
KR20230053686A (ko) Egfr 돌연변이를 갖는 비소세포 폐암의 치료
KR20230025691A (ko) 삼중 음성 유방암을 치료하기 위한 방법과 조성물
KR20250158056A (ko) 이중특이성 항-egfr/c-met 항체 및 항-pd-1 항체를 사용한 병용 요법
JP2017502025A (ja) 肉腫を治療するための組成物および方法
AU2013231846A1 (en) Combination therapies including inhibitors of the extracellular domain of E-cadherin
US20190218302A1 (en) Anti-cancer combination treatment
HK40094175A (en) Method of treating diseases using gremlin1 antagonists
EA050561B1 (ru) Лечение немелкоклеточного рака легкого с мутациями egfr
HK40128024A (zh) 双特异性抗egfr/c-met抗体和抗pd-1抗体的组合疗法
HK1194681A (en) Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
HK40053242A (en) Diagnostic and therapeutic methods for sarcomatoid kidney cancer
HK40018953A (en) Diagnostic and therapeutic methods for cancer
HK40018953B (en) Diagnostic and therapeutic methods for cancer

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190315